Scholars@Duke
Journal cover image

The truth and consequences of the COURAGE trial.

Publication ,  Journal Article
Kereiakes, DJ; Teirstein, PS; Sarembock, IJ; Holmes, DR; Krucoff, MW; O'Neill, WW; Waksman, R; Williams, DO; Popma, JJ; Buchbinder, M ...
Published in: J Am Coll Cardiol
October 16, 2007
Published version (DOI) Link to item

Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (> or =70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.

Duke Scholars

Mitchell Wolfe Krucoff
Author Mitchell Wolfe Krucoff Medicine, Cardiology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

10.1016/j.jacc.2007.07.063

EISSN

1558-3597

Publication Date

October 16, 2007

Volume

50

Issue

16

Start / End Page

1598 / 1603

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Retreatment
  • Randomized Controlled Trials as Topic
  • Platelet Aggregation Inhibitors
  • Patient Compliance
  • Myocardial Ischemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Coronary Stenosis
  • Coronary Angiography
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kereiakes, D. J., Teirstein, P. S., Sarembock, I. J., Holmes, D. R., Krucoff, M. W., O’Neill, W. W., … Stone, G. W. (2007). The truth and consequences of the COURAGE trial. J Am Coll Cardiol, 50(16), 1598–1603. https://doi.org/10.1016/j.jacc.2007.07.063
Kereiakes, Dean J., Paul S. Teirstein, Ian J. Sarembock, David R. Holmes, Mitchell W. Krucoff, William W. O’Neill, Ron Waksman, et al. “The truth and consequences of the COURAGE trial.” J Am Coll Cardiol 50, no. 16 (October 16, 2007): 1598–1603. https://doi.org/10.1016/j.jacc.2007.07.063.
Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR, Krucoff MW, O’Neill WW, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007 Oct 16;50(16):1598–603.
Kereiakes, Dean J., et al. “The truth and consequences of the COURAGE trial.” J Am Coll Cardiol, vol. 50, no. 16, Oct. 2007, pp. 1598–603. Pubmed, doi:10.1016/j.jacc.2007.07.063.
Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR, Krucoff MW, O’Neill WW, Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, Stone GW. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007 Oct 16;50(16):1598–1603.
Journal cover image

Published In

J Am Coll Cardiol

DOI

10.1016/j.jacc.2007.07.063

EISSN

1558-3597

Publication Date

October 16, 2007

Volume

50

Issue

16

Start / End Page

1598 / 1603

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Retreatment
  • Randomized Controlled Trials as Topic
  • Platelet Aggregation Inhibitors
  • Patient Compliance
  • Myocardial Ischemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Coronary Stenosis
  • Coronary Angiography